ReviewCell cycle (Georgetown, Tex.)2010
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
Review in Cell cycle (Georgetown, Tex.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Cell-Free DNA (cfDNA), Its Applications in Cancer Diagnosis and Monitoring, and Its Potential Role in Regulating Cancer Metabolism.Advances in experimental medicine and biology · 2026Review
- Immunostaining of stromal CD56 cells in ovarian malignancies.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Selectins: An Important Family of Glycan-Binding Cell Adhesion Molecules in Ovarian Cancer.Cancers · 2020Review
- Inflammation and immunity in ovarian cancer.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020Article
- Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell reports · 2018Article
- Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues.Oncotarget · 2018Article
- Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer.Scientific reports · 2018Article
- VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope.The American journal of pathology · 2016Article
- Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer.Oncotarget · 2014Article
- Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.British journal of cancer · 2014Article
- In vivo immune cell distribution of gold nanoparticles in naïve and tumor bearing mice.Small (Weinheim an der Bergstrasse, Germany) · 2014Article
- Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies.Frontiers in oncology · 2014Review
- Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.Frontiers in immunology · 2014Review
- Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.Journal of translational medicine · 2013Review
- Reprogramming immune responses via microRNA modulation.microRNA diagnostics and therapeutics · 2013Article
- The immune system in the pathogenesis of ovarian cancer.Critical reviews in immunology · 2013Review
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Oncotarget · 2012Review
- Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.Expert review of obstetrics & gynecology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Current therapies for metastatic ovarian carcinoma are based on surgical debulking followed by chemotherapy. After more than three decades implementing treatments that selectively target the tumor cell, the 5-year survival rate for metastatic ovarian cancer patients is still lower than 30%. Novel strategies are therefore urgently needed to complement classical treatments for this malignancy. Recently, leukocytes in the ovarian cancer microenvironment such as regulatory T cells and immature pro-angiogenic/tolerogenic myeloid cells have been demonstrated to play a fundamental role in tumor progression. This review focuses on our recent understanding of the potential of eliminating and/or modulating the phenotype of these leukocytes in vivo and in situ as a novel intervention to complement standard ovarian cancer treatments. The significant effects of targeting these crucial microenvironmental players on cancer vascularization, local tumor growth, distal metastatic spreading and spontaneous anti-tumor immune responses are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.